Tools & Platforms
AI Partnership Accelerates Cancer Drug Development at Onco-Innovations
Onco-Innovations (OTCQB:ONNVF) has entered into a services agreement with Redwood AI to advance the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound technology. The collaboration aims to enhance the company’s drug development capabilities through AI-driven chemistry tools.
The partnership will leverage Redwood AI’s expertise in synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the PNKP technology. The proprietary compound targets solid tumors by increasing sensitivity to radiation and DNA-damaging chemotherapies. This strategic collaboration is designed to support Onco’s progression toward First-in-Human studies by improving scalability, safety, and discovery precision.
Onco-Innovations (OTCQB:ONNVF) ha stipulato un accordo di servizi con Redwood AI per avanzare nello sviluppo della sua tecnologia esclusivamente concessa in licenza Polynucleotide Kinase Phosphatase (PNKP). La collaborazione mira a potenziare le capacità di sviluppo farmaceutico dell’azienda attraverso strumenti chimici basati sull’intelligenza artificiale.
La partnership sfrutterà l’esperienza di Redwood AI nella valutazione della sintesi, cheminformatica e previsione della tossicità specifica per organo applicata alla tecnologia PNKP. Il composto proprietario agisce contro i tumori solidi aumentando la sensibilità alla radioterapia e alle chemioterapie che danneggiano il DNA. Questa collaborazione strategica è pensata per supportare Onco nel progresso verso gli studi First-in-Human migliorando la scalabilità, la sicurezza e la precisione nella scoperta.
Onco-Innovations (OTCQB:ONNVF) ha firmado un acuerdo de servicios con Redwood AI para avanzar en el desarrollo de su tecnología de compuestos Polynucleotide Kinase Phosphatase (PNKP) con licencia exclusiva. La colaboración busca mejorar las capacidades de desarrollo de fármacos de la empresa mediante herramientas químicas impulsadas por inteligencia artificial.
La asociación aprovechará la experiencia de Redwood AI en la evaluación de síntesis, quimioinformática y predicción de toxicidad específica por órgano para la tecnología PNKP. El compuesto patentado está dirigido a tumores sólidos aumentando la sensibilidad a la radiación y quimioterapias que dañan el ADN. Esta colaboración estratégica está diseñada para apoyar el avance de Onco hacia los estudios First-in-Human mejorando la escalabilidad, seguridad y precisión en el descubrimiento.
Onco-Innovations (OTCQB:ONNVF)는 Redwood AI와 독점 라이선스된 Polynucleotide Kinase Phosphatase (PNKP) 화합물 기술 개발을 촉진하기 위한 서비스 계약을 체결했습니다. 이번 협력은 AI 기반 화학 도구를 통해 회사의 신약 개발 역량을 강화하는 것을 목표로 합니다.
이번 파트너십은 PNKP 기술에 대해 합성 평가, 화학정보학, 장기별 독성 예측 분야에서 Redwood AI의 전문성을 활용합니다. 이 독점 화합물은 방사선 및 DNA 손상 화학요법에 대한 민감도를 높여 고형암을 표적으로 합니다. 이 전략적 협력은 확장성, 안전성 및 발견 정확성을 향상시켜 Onco의 First-in-Human 연구 진전을 지원하기 위해 설계되었습니다.
Onco-Innovations (OTCQB:ONNVF) a conclu un accord de services avec Redwood AI pour faire avancer le développement de sa technologie exclusive de composés Polynucleotide Kinase Phosphatase (PNKP). Cette collaboration vise à renforcer les capacités de développement pharmaceutique de l’entreprise grâce à des outils chimiques pilotés par l’intelligence artificielle.
Le partenariat exploitera l’expertise de Redwood AI en évaluation de synthèse, chimiométrie et prédiction de toxicité spécifique aux organes pour la technologie PNKP. Le composé propriétaire cible les tumeurs solides en augmentant leur sensibilité à la radiothérapie et aux chimiothérapies endommageant l’ADN. Cette collaboration stratégique est conçue pour soutenir la progression d’Onco vers les études First-in-Human en améliorant l’évolutivité, la sécurité et la précision de la découverte.
Onco-Innovations (OTCQB:ONNVF) hat eine Dienstleistungsvereinbarung mit Redwood AI geschlossen, um die Entwicklung seiner exklusiv lizenzierten Polynucleotide Kinase Phosphatase (PNKP) Verbindungstechnologie voranzutreiben. Die Zusammenarbeit zielt darauf ab, die Wirkstoffentwicklung des Unternehmens durch KI-gestützte Chemie-Tools zu verbessern.
Die Partnerschaft nutzt Redwood AIs Expertise in Syntheseevaluierung, Cheminformatik und organspezifischer Toxizitätsvorhersage für die PNKP-Technologie. Die proprietäre Verbindung zielt auf solide Tumore ab, indem sie die Empfindlichkeit gegenüber Strahlung und DNA-schädigenden Chemotherapien erhöht. Diese strategische Zusammenarbeit soll Oncos Fortschritt zu First-in-Human-Studien durch verbesserte Skalierbarkeit, Sicherheit und Entdeckungspräzision unterstützen.
Positive
- Partnership with AI-driven platform could accelerate drug development timeline and reduce costs
- Access to advanced tools for synthesis evaluation and toxicity prediction
- Technology targets multiple solid tumors with potential to enhance treatment effectiveness
- Strategic advancement toward First-in-Human studies
Negative
- Still in preclinical phase with no immediate revenue potential
- Success of AI implementation in drug development remains unproven
VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) (“Onco” or the “Company“) is pleased to announce that it has entered into a services agreement with Redwood AI Inc. (Redwood AI). This collaboration marks continued advancement of Onco’s mission to accelerate the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound (the “Technology”) and to extend its proprietary knowledge through discovery. This proprietary compound aims to target a range of solid tumours by enhancing sensitivity to radiation and DNA-damaging chemotherapies, offering the potential to exploit specific genetic susceptibilities in cancer. Through this agreement with Redwood AI, Onco gains access to Redwood AI’s AI-driven chemistry tools that have the potential to unlock critical efficiencies in drug development, thereby carrying the potential to reduce synthesis complexity, refine compound design, and expand the pipeline of viable analogs. This effort is aimed at reinforcing Onco’s technical capabilities at a crucial preclinical phase, with the goal of improving scalability, safety, and discovery precision.
Under the scope of the agreement, Redwood AI will provide multi-pronged support across synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the Technology and its structural analogs. This includes independent reviews of third-party chemistry proposals and the use of Redwood’s proprietary in-silico modelling tools. In simpler terms, these efforts are intended to deepen Onco’s understanding of its Technology by supporting structure-based refinement and mechanistic insight. These efforts are part of Onco’s broader strategy to efficiently progress toward First-in-Human studies.
Redwood AI is a Vancouver-based artificial intelligence company harnessing artificial intelligence to accelerate drug synthesis and development. Founded by a team with deep roots in chemistry, AI, and drug manufacturing, including origins from Stanford1, Redwood AI is focused on overcoming one of the pharmaceutical industry’s most persistent challenges – drug synthesis. By automating a substantial portion of the traditionally manual steps involved in synthesis, Redwood’s technology aims to support more accurate, scalable, and cost-effective drug creation, with the goal of helping research teams move from discovery to development faster and with greater efficiency.
“The pace of innovation in cancer therapeutics depends on how quickly we can turn complex data into actionable decisions. Redwood AI’s platform has the potential to enable us to explore synthesis strategies, evaluate risks, and optimize compound design with greater speed and precision. This kind of insight not only strengthens our scientific direction but also has the potential to accelerate our timeline towards clinical trials,” stated Thomas O’Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
“Thomas O’Shaughnessy“
Chief Executive Officer
For more information, please contact:
Thomas O’Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company’s business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “potential”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What is the partnership between Onco-Innovations (ONNVF) and Redwood AI?
Onco-Innovations has signed a services agreement with Redwood AI to advance its PNKP inhibitor technology using AI-driven chemistry tools for drug development, synthesis evaluation, and toxicity prediction.
How does Onco-Innovations’ PNKP compound technology work?
The technology targets solid tumors by enhancing sensitivity to radiation and DNA-damaging chemotherapies, exploiting specific genetic susceptibilities in cancer.
What are the main benefits of the Redwood AI partnership for ONNVF?
The partnership provides access to AI-driven tools that can reduce synthesis complexity, refine compound design, and expand the pipeline of viable analogs, potentially accelerating the path to clinical trials.
What is the current development stage of Onco-Innovations’ PNKP technology?
The technology is in the preclinical phase, with the company working toward First-in-Human studies.
How will Redwood AI’s technology benefit Onco-Innovations’ drug development process?
Redwood AI’s platform will help explore synthesis strategies, evaluate risks, and optimize compound design with greater speed and precision, potentially accelerating the timeline toward clinical trials.
Tools & Platforms
Unisound AI Technology (SEHK:9678): Does the Current Valuation Reflect Future Growth Potential?

Unisound AI Technology (SEHK:9678) caught the attention of investors this week with a move in its share price, prompting debate about what might be driving momentum, or if it signals fresh risks or opportunity for the company. While there hasn’t been a clear event or announcement to point to, these kinds of movements often act as a spark for investors to take a closer look at what’s happening under the hood, especially when it comes to future prospects versus the current price tag.
Stepping back, Unisound AI Technology’s performance over the year has painted a mixed picture. After gaining nearly 99% year-to-date, the stock has seen a more subdued run lately, with a modest uptick over the past day but declines across the month and week. For a company with ambitions in AI technology, such swings are a reminder that investors are constantly fine-tuning their expectations, whether that’s in response to sector enthusiasm, competitive concerns, or changes in risk appetite.
So is the recent slip a sign that the shares are set up for a rebound, or are markets wisely factoring in the next chapter of growth already? Let’s dig into the valuation to see what the numbers tell us.
Price-to-Sales of 22.3x: Is it justified?
Unisound AI Technology currently trades at a price-to-sales (P/S) ratio of 22.3, making it appear significantly more expensive than both the Hong Kong Software industry average (2.8x) and its closest peers (6.3x).
The price-to-sales ratio compares a company’s market value to its revenue, serving as a key measure for businesses that are not yet profitable. For technology and software firms, investors often use P/S when earnings are negative or volatile, as it provides a way to assess how much the market is willing to pay for each unit of sales.
A P/S ratio this elevated suggests investors are pricing in substantial growth or market dominance in the future. However, such a premium also signals heightened expectations. Unisound must deliver meaningful revenue acceleration to justify this multiple, especially given its current unprofitability.
Result: Fair Value of $589.00 (OVERVALUED)
See our latest analysis for Unisound AI Technology.
However, weak revenue growth and sustained losses remain key risks. These factors could undermine the high valuation and dampen near-term investor confidence.
Find out about the key risks to this Unisound AI Technology narrative.
Another View: What Does Our DCF Model Say?
Taking a different approach, our SWS DCF model also sizes up Unisound AI Technology but finds no reason to challenge the lofty price. It flags the stock as overvalued based on future cash flows. Could this reinforce market caution, or is there still something the market sees that is missed in the numbers?
Look into how the SWS DCF model arrives at its fair value.
Stay updated when valuation signals shift by adding Unisound AI Technology to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.
Build Your Own Unisound AI Technology Narrative
If you have a different perspective or want to dig into the numbers yourself, you can easily craft your own assessment in just a few minutes. Do it your way.
A great starting point for your Unisound AI Technology research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
Looking for more investment ideas?
Smart investors keep their eyes open for every opportunity. Don’t limit your research to one stock when you could be finding tomorrow’s standouts right now.
- Spot undervalued companies with robust cash flow using our powerful tool for those seeking undervalued stocks based on cash flows in overlooked corners of the market: undervalued stocks based on cash flows
- Unlock the income potential of markets and track high-yield opportunities with our selection of dividend stocks with yields > 3%: dividend stocks with yields > 3%
- Stay on the forefront of digital innovation by tracking the movers and shakers among cryptocurrency and blockchain stocks that are powering the next financial revolution: cryptocurrency and blockchain stocks
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Tools & Platforms
Rochester Cloud Connect Summit to Feature Nationally-Recognized AI, Cyber Experts
FirstLight Announces High-Impact Cloud Connect Summit in Rochester, Showcasing Leaders in Cybersecurity, AI, and Cloud Innovation
ALBANY, N.Y., Sept. 11, 2025 /PRNewswire/ — FirstLight, a leading provider of digital infrastructure services to enterprise and carrier customers throughout the Northeast and mid-Atlantic, is bringing its highly anticipated Cloud Connect Summit to Rochester, NY. The event will take place October 2nd at the historic George Eastman Museum, gathering technology leaders and innovators for an afternoon of forward-looking insights, powerful discussions, and high-level networking.
Known as one of the premier IT events in the region, Cloud Connect Summit brings together top minds in cybersecurity, artificial intelligence, and cloud computing to explore the trends and technologies reshaping today’s digital landscape. FirstLight is proud to serve as title sponsor, with additional sponsorship from industry leaders Veeam and Ciena.
The speaker lineup features an impressive roster of thought leaders and innovators:
- Colonel Craig E. Frank, Director of S-6 (Communications) at Space Systems Command, Los Angeles Air Force Base — leading a team of 85 specialists in cybersecurity, digital engineering, and technology strategy.
- Matthew Wright, PhD, Kevin O’Sullivan Endowed Professor and Chair of Cybersecurity at Rochester Institute of Technology — a globally recognized researcher with over 100 peer-reviewed publications on cybersecurity, human-computer interaction, and networks.
- Rick Vanover, Senior Director of Product Strategy at Veeam — presenting the latest insights from a sweeping survey of 1,000 companies on ransomware resilience and defense strategies.
- Erich Kron, cybersecurity speaker, author, and KnowBe4 expert — a seasoned security leader with decades of experience across information security, project management, and senior leadership roles.
The day’s program will include dynamic presentations, interactive discussions, and actionable takeaways, capped off with cocktails and networking among peers and industry experts.
“This is more than an event – it’s a forum for sparking ideas, sharing strategies, and connecting with the people shaping the future of AI and Cybersecurity,” said Lorenzo Leuzzi, Chief Revenue Officer at FirstLight.
Registration is now open at www.cloudconnectsummit.com. For a limited time, attendees can waive the registration fee with code “FirstLight.”
About FirstLight Fiber, Inc.
FirstLight, headquartered in Albany, New York, provides fiber-optic data, Internet, data center, cloud, unified communications, and managed services to enterprise and carrier customers throughout the Northeast and mid-Atlantic with more than 125,000 locations serviceable by our more than 25,000-route mile network. FirstLight offers a robust suite of advanced telecommunications products featuring a comprehensive portfolio of high bandwidth connectivity solutions including Ethernet, wavelength and dark fiber services as well as dedicated Internet access solutions, data center, cloud and voice services. FirstLight’s clientele includes national cellular providers and wireline carriers and many leading enterprises, spanning high tech manufacturing and research, hospitals and healthcare, banking and financial, secondary education, colleges and universities, and local and state governments.
To learn more about FirstLight, visit www.firstlight.net, or follow the company on X, LinkedIn and Instagram.
Media Contact:
John Romagnoli
[email protected]
SOURCE FirstLight Fiber
Tools & Platforms
Reimagining the role of medical science liaisons in the age of AI

Content generation: The low-hanging fruit
Medical affairs teams spend a lot of their time generating different kinds of content, including regulatory writing, educational materials, and conference presentations. Although this content certainly needs to be reviewed by humans for accuracy, AI can be, and in many cases already is being, used to speed up the process of content generation.
“If someone today is a medical writer at Pfizer and they’re drafting peer-reviewed publications for Pfizer’s phase 3 clinical trials, the drafting of that publication is a total waste of time,” Katz said. “AI could draft that publication quicker, faster, better, and the person should be a reviewer instead of an author, basically. Their function changes. That’s a good example. Another example is someone that’s creating a poster for ASCO. Why are you formatting this thing? AI can create a much prettier poster in 10 seconds than you can ever create, and you should edit it instead of author it.”
MSLs themselves also need to generate a lot of content to do their work connecting with HCPs.
“Generating content is a large part of what we do,” said Malloy. “Patient lay summaries, manuscripts, you name it. We are trying to augment their capability to do exactly what they’ve been doing for years.”
Administrative support: A huge opportunity
Stewart mentioned that her early career as an MSL involved a lot of spreadsheets and detective work. But increasingly, that work can be done by AI systems.
“It’s cut the administrative work down significantly, and we’re able to do things much faster and be more agile with that work,” Stewart said. “I mean, of course, what I’m finding is there’s always a need to validate the information that’s given to us when it’s generated through an AI model, but it’s such a time saver. We’re able to get way more done with fewer people on the team than we were when I first started.”
But administrative support goes beyond insights generation. AI can also help MSLs manage their schedules and responsibilities more efficiently.
H1’s whole business is built around creating a database that makes it easier for MSLs to find out everything they need to know about healthcare providers, from their areas of expertise to what conferences they’re planning to attend. Now they are building AI agents that sit on top of that database.
“For BioMarin, we created a digital MSL who basically every day monitors the latest HCP’s information, recommends what you should do with that HCP, it predicts what that HCP will do,” Katz said. “It can then automate all your emails that you want to send them, do follow-up meetings, monitor the latest scientific literature. You can have it draft or automatically send the emails. It just reduces everything that an MSL needs to do. It sits on top of an MSL. Each MSL is paired with a digital MSL, and boom, that’s what they do for you.”
Training: Improving MSL soft skills
While information management is a huge part of an MSL’s job, equally important are the soft skills of connecting to healthcare providers, gaining their trust, and building a rapport. This is the part of the job where the human element is the most important. But AI can still be helpful.
“Because they are so well-versed and they do that constant upkeep and research into their field, MSLs have an understanding of the science that’s really very solid,” Malloy said. “But it’s in that relationship management, conversational skill building that we noticed a real gap. That’s where the MSL Interact tool really comes into play. It’s filling that gap, that need for MSLs to feel confident.”
MSL Interact is a training platform developed by Inizio that leverages the ability of large language models to take on different personas as they interact with users.
“What we’re doing is taking generative AI, training it, giving it a persona, ingesting information that is both publicly available and that is client-specific. We’re targeting different therapeutic areas. We’re engaging clients. They’re giving us their specific information,” Malloy explained. “We’re able to create this HCP persona that maps to different types of doctors or healthcare providers that these MSLs may be meeting in the field. Then the MSLs can come into the tool and actually have a practice conversation.
-
Business2 weeks ago
The Guardian view on Trump and the Fed: independence is no substitute for accountability | Editorial
-
Tools & Platforms1 month ago
Building Trust in Military AI Starts with Opening the Black Box – War on the Rocks
-
Ethics & Policy2 months ago
SDAIA Supports Saudi Arabia’s Leadership in Shaping Global AI Ethics, Policy, and Research – وكالة الأنباء السعودية
-
Events & Conferences4 months ago
Journey to 1000 models: Scaling Instagram’s recommendation system
-
Jobs & Careers2 months ago
Mumbai-based Perplexity Alternative Has 60k+ Users Without Funding
-
Podcasts & Talks2 months ago
Happy 4th of July! 🎆 Made with Veo 3 in Gemini
-
Education2 months ago
VEX Robotics launches AI-powered classroom robotics system
-
Education2 months ago
Macron says UK and France have duty to tackle illegal migration ‘with humanity, solidarity and firmness’ – UK politics live | Politics
-
Funding & Business2 months ago
Kayak and Expedia race to build AI travel agents that turn social posts into itineraries
-
Podcasts & Talks2 months ago
OpenAI 🤝 @teamganassi